文献速递胸部肿瘤消化系统肿瘤乳腺癌

2020至2050年204个国家和地区29种癌症的全球经济成本估计与预测

Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050.
PubMed 文献 · JAMA Oncol · 2023-01-01

该决策分析模型纳入经济反馈,评估劳动力与投资相关的健康结局,估算2020至2050年204个国家和地区29种癌症的经济成本。结果显示全球癌症经济成本为25.2万亿国际元(2017年不变价),相当于全球国内生产总值每年0.55%的税负;气管、支气管和肺癌占比最高(15.4%),中国和美国绝对经济成本最大,分别占全球负担的24.1%和20.8%。

要点

  • 2020至2050年全球癌症经济成本估计为25.2万亿国际元(2017年不变价),相当于全球GDP每年0.55%的税负。
  • 经济成本最高的5种癌症为气管、支气管和肺癌(15.4%)、结直肠癌(10.9%)、乳腺癌(7.7%)、肝癌(6.5%)和白血病(6.3%)。
  • 中国和美国绝对经济成本最大,分别占全球负担的24.1%和20.8%;75.1%的癌症死亡发生在中低收入国家,但其经济成本占比为49.5%。

核心结论

  • 在这项决策分析建模研究中,癌症的宏观经济成本巨大,且在癌种、国家和世界区域间分布不均。
  • 研究结果提示,全球努力遏制癌症持续负担是必要的。

研究设计与样本

  • 决策分析模型,在评估与劳动力和投资相关的健康结局时纳入经济反馈。
  • 宏观经济模型用于考虑:癌症相关死亡和发病与劳动力供给的关联;受癌症影响人群在教育、经验和劳动力市场参与方面的年龄-性别差异;以及癌症治疗费用从储蓄和投资中的转移。
  • 数据收集于2022年4月25日,覆盖204个国家和地区的29种癌症。

主要发现

  • 2020至2050年全球癌症经济成本估计为25.2万亿国际元(2017年不变价),相当于全球国内生产总值每年0.55%的税负。
  • 经济成本最高的5种癌症为:气管、支气管和肺癌(15.4%)、结直肠癌(10.9%)、乳腺癌(7.7%)、肝癌(6.5%)和白血病(6.3%)。
  • 中国和美国绝对经济成本最大,分别占全球总负担的24.1%和20.8%。
  • 75.1%的癌症死亡发生在中低收入国家,但其癌症经济成本占比为49.5%。
  • 治疗费用对癌症总经济成本的相对贡献在高收入国家大于低收入国家。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cancers are a leading cause of mortality, accounting for nearly 10 million annual deaths worldwide, or 1 in 6 deaths. Cancers also negatively affect countries' economic growth. However, the global economic cost of cancers and its worldwide distribution have yet to be studied. OBJECTIVE: To estimate and project the economic cost of 29 cancers in 204 countries and territories. DESIGN, SETTING, AND PARTICIPANTS: A decision analytical model that incorporates economic feedback in assessing health outcomes associated with the labor force and investment. A macroeconomic model was used to account for (1) the association of cancer-related mortality and morbidity with labor supply; (2) age-sex-specific differences in education, experience, and labor market participation of those who are affected by cancers; and (3) the diversion of cancer treatment expenses from savings and investments. Data were collected on April 25, 2022. MAIN OUTCOMES AND MEASURES: Economic cost of 29 cancers across countries and territories. Costs are presented in international dollars at constant 2017 prices. RESULTS: The estimated global economic cost of cancers from 2020 to 2050 is $25.2 trillion in international dollars (at constant 2017 prices), equivalent to an annual tax of 0.55% on global gross domestic product. The 5 cancers with the highest economic costs are tracheal, bronchus, and lung cancer (15.4%); colon and rectum cancer (10.9%); breast cancer (7.7%); liver cancer (6.5%); and leukemia (6.3%). China and the US face the largest economic costs of cancers in absolute terms, accounting for 24.1% and 20.8% of the total global burden, respectively. Although 75.1% of cancer deaths occur in low- and middle-income countries, their share of the economic cost of cancers is lower at 49.5%. The relative contribution of treatment costs to the total economic cost of cancers is greater in high-income countries than in low-income countries. CONCLUSIONS AND RELEVANCE: In this decision analytical modeling study, the macroeconomic cost of cancers was found to be substantial and distributed heterogeneously across cancer types, countries, and world regions. The findings suggest that global efforts to curb the ongoing burden of cancers are warranted.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Chen S, Cao Z, Prettner K, et al. Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncol. 2023. PMID: 36821107. doi:10.1001/jamaoncol.2022.7826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。